Actualités

Moderna reported its Q2 update alongside news that its lead norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, so the trial will continue for further evaluation. The company is awaiting an FDA decision on its seasonal influenza vaccine, mFLUSIVA, which is expected by early August. Management paired these pipeline updates with Q2 results that were ahead of expectations and a revised outlook for operating expenses. For investors watching...

Moby summary of Moderna, Inc.'s Q2 2026 earnings call

Moderna Inc (MRNA) exceeds Q2 revenue guidance and advances key vaccines, but faces delays in norovirus trial and oncology readouts.

Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.

The company topped Wall Street loss estimates, but its norovirus vaccine missed a key trial goal, sending shares lower

Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases. The company posted a net loss of $782 million, or $1.97 per sha

Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Moderna narrowed its loss in the recent quarter as revenue climbed, boosted by deliveries made under a government contract in the U.K.

Find insight on Sanofi, Haleon, Cochlear and more in the latest Market Talks covering the health care sector.

The benchmark US stock measures were tracking in the green before the open Friday as Amazon's (AMZN)

Moderna posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.

Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.1% year on year to $145 million. Its GAAP loss of $1.97 per share was 4.2% above analysts’ consensus estimates.

There are fresh signs that fusion power startup Commonwealth Fusion Systems will list in the next two to three years.

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results this Friday before market hours. Here’s what investors should know.

Today Earnings (a.m.): Mastercard, Hershey, KKR, Yum Brands, Cigna, Regeneron, Valero Energy, Norwegian Cruise Line, Hyatt Hotels, Bristol-Myers Squibb, Altria, International Paper, SiriusXM, Blue Owl Capital Earnings (p.

MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.

Moderna stock has delivered a strong 70.9% gain over the past year, but the longer track record and current valuation checks suggest the shares are not clearly priced as a bargain right now. Over five years, Moderna shareholders have seen the stock decline 85.6%, which puts the recent rebound in a much longer and still challenging context. Progress on the mRNA cancer program, including the recent Phase 1 trial start for mRNA-4200, can support sentiment on Moderna’s growth potential. At the...

The year 2026 has turned into a pivotal year for the biotech capital markets. Venture funding for biotech firms reached $9.1 billion in the first half of the year, the highest total since 2022, with 38 acquisitions being completed over the same period, marking the sector’s greatest M&A pace in at least seven years. Underneath […]

In recent months, Moderna reported a very large year-on-year Q1 revenue increase that surpassed analyst expectations, secured two European approvals including the world’s first flu plus COVID combination vaccine mCOMBRIAX, and began a pivotal Phase 3 trial for its lung cancer candidate intismeran. This combination of new product approvals and late-stage oncology pipeline progress highlights Moderna’s effort to broaden its business well beyond its COVID-19 franchise. We’ll now examine how the...

FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 14.3% over the past six months while the S&P 500 was up 6.3%.

Moderna has already surged more than 80% in 2026, but two major events packed into the next two weeks could either cement that rally or unravel it fast.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at therapeutics stocks, starting with Moderna (NASDAQ:MRNA).

In the most recent trading session, Moderna (MRNA) closed at $55.63, indicating a +2.89% shift from the previous trading day.

Moderna's stock recently hit a new 52-week high after receiving positive news surrounding one of its vaccines.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Moderna (NASDAQ:MRNA) and its peers.

The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that could sharply reshape valuations overnight.

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Despite challenges in life sciences and European automotive sectors, Dassault Systemes SE (DASTF) reports robust revenue growth and strategic advancements in AI and cloud solutions.

With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.